A Cross-Sectional Survey of Medical Cannabis Users: Patterns of Use and Perceived Efficacy

Cannabis and Cannabinoid Research

Volumn 1, Issue 1, 2016, Pages 131-138

  Sexton, Michelle ^a   Cuttler, Carrie ^b   Finnell, John S ^c   Mischley, Laurie K ^d  

^a Center for the Study of Cannabis and Social Policy   (United States)

^b WASHINGTON STATE UNIVERSITY   (United States)

^c Graduate School of Integrative Medicine   (United States)

^d BASTYR UNIVERSITY   (United States)

Author keywords

Cannabis; health effects; medical Cannabis; survey; use patterns

Indexed keywords

MEDICAL CANNABIS;

ADOLESCENT; ADULT; AGED; ANOREXIA; ANXIETY DISORDER; ARTHRITIS; ARTICLE; ATTITUDE TO HEALTH; CROHN DISEASE; CROSS-SECTIONAL STUDY; DEPRESSION; DRUG EFFICACY; DRUG USE; EPILEPSY; FEMALE; GLAUCOMA; GLOBAL HEALTH; GOBAL HEALTH SCORE; HEADACHE; HEALTH STATUS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INTRACTABLE PAIN; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; MALIGNANT NEOPLASM; MENTAL HEALTH; MIDDLE AGED; MIGRAINE; MULTIPLE SCLEROSIS; NAUSEA; ONLINE ANALYSIS; PAIN; PHYSICAL PARAMETERS; POPULATION RESEARCH; PRESCRIPTION; PRIORITY JOURNAL; SCORING SYSTEM; SEIZURE; SOCIAL MEDIA; SPASTICITY; SYMPTOM; TIC; TREMOR; ULCERATIVE COLITIS; WASHINGTON; YOUNG ADULT;

EID: 85021438583     PISSN: None     EISSN: 23788763     Source Type: Journal    
DOI: 10.1089/can.2016.0007     Document Type: Article

References (58)

1. Russo EB. History of cannabis and its preparations in saga, science, and sobriquet. Chem Biodivers. 2007;4:1614-1648.
2. State Marijuana Laws Map. Dr. Mark Funkhouser, 2015. Available at: www.governing.com/gov-data/state-marijuana-laws-map-medicalrecreational. html (Accessed January 19, 2015).
3. Aggarwal SK. Cannabinergic pain medicine: a concise clinical primer and survey of randomized-controlled trial results. Clin J Pain. 2013;29:162-171.
4. Ben Amar M. Cannabinoids in medicine: a review of their therapeutic potential. J Ethnopharmacol. 2006;105:1-25.
5. Betthauser K, Pilz J, Vollmer LE. Use and effects of cannabinoids in military veterans with posttraumatic stress disorder. Am J Health Syst Pharm. 2015;72:1279-1284.
6. Koppel BS, Brust JC, Fife T, et al. Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: Report of the Guideline Development Subcommittee of the American Academy of Neurology. Neurology. 2014;82:1556-1563.
7. Lynch ME, Campbell F. Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials. Br J Clin Pharmacol. 2011;72:735-744.
8. Baron EP. Comprehensive review of medicinal marijuana, cannabinoids, and therapeutic implications in medicine and headache: what a long strange trip it's been. Headache. 2015;55:885-916.
9. ProCon.org. 23 Legal Medical Marijuana States and DC. 2015. Available at: http://medicalmarijuana.procon.org/view.resource.php?resourceID= 000881 (Accessed March 11, 2015).
10. Reiman A. Medical cannabis patients: patient profiles and health care utilization patterns. Complement Health Pract Rev. 2007;12:31-49.
11. Barnwell SS, Earleywine M, Wilcox R. Cannabis, motivation, and life satisfaction in an internet sample. Subst Abuse Treat Prev Policy. 2006;1:2.
12. Reinarman C, Nunberg H, Lanthier F, et al. Who are medical marijuana patients? Population characteristics from nine California assessment clinics. J Psychoactive Drugs. 2011;43:128-135.
13. Webb CW, Webb SM. Therapeutic benefits of cannabis: a patient survey. Hawaii J Med Public Health. 2014;73:109-111.
14. Hazekamp A, Ware MA, Muller-Vahl KR, et al. The medicinal use of cannabis and cannabinoids-an international cross-sectional survey on administration forms. J Psychoactive Drugs. 2013;45:199-210.
15. Walsh Z, Callaway R, Belle-Isle L, et al. Cannabis for therapeutic purposes: patient characteristics, access, and reasons for use. Int J Drug Policy. 2013;24:511-516.
16. Survey of Cannabis Use. 2013. Available at: www.bastyr.edu/research/ studies/survey-cannabis-use. (Accessed April 21, 2015).
17. Harris PA, Taylor R, Thielke R, et al. Research electronic data capture (REDCap)-A metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
18. Hays RD, Bjorner JB, Revicki DA, et al. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items. Quality Life Res. 2009;18:873-880.
19. Tabachnick BG, Fidell LS. Using multivariate statistics. 4th ed. Allyn and Bacon: Boston, MA, 2001.
20. Center for Drug Evaluation and Research. Guidance for industry: patientreported outcome measures: use in medical product developments to support labeling claims. In: U.S. Department of Health and Human Services, ed. Food and Drug Administration: Rockfield, MD, 2006.
21. Osborn LA, Lauritsen KJ, Cross N, et al. Self-medication of somatic and psychiatric conditions using botanical marijuana. J Psychoactive Drugs. 2015;47:345-350.
22. Gobira PH, Almeida-Santos AF, Guimaraes FS, et al. Role of the endocannabinoid 2-arachidonoylglycerol in aversive responses mediated by the dorsolateral periaqueductal grey. Eur Neuropsychopharmacol. 2016;26:15-22.
23. Gray JM, Wilson CD, Lee TT, et al. Sustained glucocorticoid exposure recruits cortico-limbic CRH signaling to modulate endocannabinoid function. Psychoneuroendocrinology. 2016;66:151-158.
24. Lazary J, Eszlari N, Juhasz G, et al. Genetically reduced FAAH activity may be a risk for the development of anxiety and depression in persons with repetitive childhood trauma. Eur Neuropsychopharmacol 2016. [Epub ahead of print]; DOI: 10.1016/j.euroneuro.2016.03.003.
25. Schier AR, Ribeiro NP, Silva AC, et al. Cannabidiol, a Cannabis sativa constituent, as an anxiolytic drug. Rev Bras Psiquiatr. 2012;34:S104-S110.
26. Gaetani S, Dipasquale P, Romano A, et al. The endocannabinoid system as a target for novel anxiolytic and antidepressant drugs. Int Rev Neurobiol. 2009;85:57-72.
27. Bhattacharyya S, Fusar-Poli P, Borgwardt S, et al. Modulation of mediotemporal and ventrostriatal function in humans by Delta9-tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Arch Gen Psychiatry. 2009;66:442-451.
28. Gomes FV, Resstel LB, Guimaraes FS. The anxiolytic-like effects of cannabidiol injected into the bed nucleus of the stria terminalis are mediated by 5-HT1A receptors. Psychopharmacology. 2011;213: 465-473.
29. Campos AC, Moreira FA, Gomes FV, et al. Multiple mechanisms involved in the large-spectrum therapeutic potential of cannabidiol in psychiatric disorders. Philos Trans R Soc Lond B Biol Sci. 2012;367:3364-3378.
30. de Mello Schier AR, de Oliveira Ribeiro NP, Coutinho DS, et al. Antidepressant-like and anxiolytic-like effects of cannabidiol: a chemical compound of Cannabis sativa. CNS Neurol Disord Drug Targets. 2014;13:953-960.
31. Aggarwal SK, Carter GT, Sullivan MD, et al. Prospectively surveying healthrelated quality of life and symptom relief in a lot-based sample of medical cannabis-using patients in urban Washington State reveals managed chronic illness and debility. Am J Hosp Palliat Care. 2013;30:523-531.
32. Ware MA, Adams H, Guy GW. The medicinal use of Cannabis in the UK: results of a nationwide survey. Int J Clin Pract. 2005;59:291-295.
33. Reiman A. Cannabis as a substitute for alcohol and other drugs. Harm Reduct J. 2009;6:35.
34. Manchikanti L, Helm S, 2nd, Fellows B, et al. Opioid epidemic in the United States. Pain Physician. 2012;15:ES9-ES38.
35. Hartman RL, Brown TL, Milavetz G, et al. Controlled cannabis vaporizer administration: blood and plasma cannabinoids with and without alcohol. Clin Chem. 2015;61:850-869.
36. Eisenberg E, Ogintz M, Almog S. The pharmacokinetics, efficacy, safety, and ease of use of a novel portable metered-dose cannabis inhaler in patients with chronic neuropathic pain: a phase 1a study. J Pain Palliat Care Pharmacother. 2014;28:216-225.
37. Jensen RP, Luo W, Pankow JF, et al. Hidden formaldehyde in e-cigarette aerosols. N Engl J Med. 2015;372:392-394.
38. Zajicek JP, Hobart JC, Slade A, et al. Multiple sclerosis and extract of cannabis: results of the MUSEC trial. J Neurol Neurosurg Psychiatry. 2012;83:1125-1132.
39. Wade DT, Makela P, Robson P, et al. Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients. Mult Scler. 2004;10:434-441.
40. Wade DT, Robson P, House H, et al. A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms. Clin Rehabil. 2003;17:21-29.
41. Adams R, Pease DC, Clark JH. Isolation of cannabinol, cannabidiol and quebrachitol from red oil of Minnesota wild hemp. J Am Chem Soc. 1940;62:2194-2196.
42. Wollner HJ, Matchett JR, Levine J, et al. Isolation of a physiologically active tetrahydrocannbinol from cannabis sativa resin. J Am Chem Soc. 1942;64:26-29.
43. Gaoni Y, Mechoulam, R. Isolation, structure and partial synthesis of an active constituent of hashish. J Am Chem Soc. 1964;86:1646-1647.
44. Bergamaschi MM, Queiroz RH, Chagas MH, et al. Cannabidiol reduces the anxiety induced by simulated public speaking in treatment-naive social phobia patients. Neuropsychopharmacology. 2011;36:1219-1226.
45. Crippa JA, Derenusson GN, Ferrari TB, et al. Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. J Psychopharmacol. 2011;25:121-130.
46. Zuardi AW, Shirakawa I, Finkelfarb E, et al. Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects. Psychopharmacology. 1982;76:245-250.
47. Englund A, Morrison PD, Nottage J, et al. Cannabidiol inhibits THC-elicited paranoid symptoms and hippocampal-dependent memory impairment. J Psychopharmacol. 2013;27:19-27.
48. Small E. Evolution and classification of cannabis sativa (marijuana, hemp) in relation to human utilization. Bot Rev. 2015;81:189-294.
49. Clarke RC, Merlin MD. Letter to the editor: Small, Ernest. 2015 evolution and classification of cannabis sativa (marijuana, hemp) in relation to human utilization. Bot Rev. 2015;81:295-305.
50. Piomelli D, Russo EB. The cannabis sativa versus cannabis indica debate: an interview with Ethan Russo, MD. Cannabis Cannabinoid Res. 2015;1:44-46.
51. Giese MW, Lewis MA, Giese L, et al. Development and validation of a reliable and robust method for the analysis of cannabinoids and terpenes in cannabis. J AOAC Int. 2015;98:1503-1522.
52. Office of Minority Affairs and Diversity. Changing demographics by race/ ethnicity and socioeconomic status in Washington State. University of Washington: Seattle, WA, 2013.
53. Golub A, Johnson BD, Dunlap E. The race/ethnicity disparity in misdemeanor marijuana arrests in New York City. Criminol Public Policy. 2007;6:131-164.
54. Ramchand R, Pacula RL, Iguchi MY. Racial differences in marijuanausers' risk of arrest in the United States. Drug Alcohol Depend. 2006;84:264-272.
55. Roy-Burne P, Maynard C, Bumgardner K, et al. Are medical marijuana users diffeent from recreational users? The view from primary care. Am J Addict. 2015;24:599-606.
56. Ryan-Ibarra S, Induni M, Ewing D. Prevalence of medical marijuana use in California, 2012. Drug Alcohol Rev 2015;34:141-146.
57. United States Annual Census. QuickFacts: King County, Washington. 2016. Available at: www.census.gov/quickfacts/table/PST045215/53033 (Accessed May 27, 2016).
58. American Public Health Association. Regulating Commercially Legalized Marijuana as a Public Health Priority. 2014, November 18.